Danaher Corporation $DHR Shares Sold by Parsons Capital Management Inc. RI

Parsons Capital Management Inc. RI trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 38.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,450 shares of the conglomerate’s stock after selling 17,463 shares during the quarter. Parsons Capital Management Inc. RI’s holdings in Danaher were worth $5,423,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in DHR. Nuveen LLC acquired a new position in shares of Danaher during the first quarter worth about $833,941,000. Invesco Ltd. grew its position in Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after buying an additional 1,450,703 shares during the period. Baird Financial Group Inc. increased its holdings in Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after buying an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP lifted its position in shares of Danaher by 33.2% during the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock valued at $651,515,000 after acquiring an additional 791,662 shares during the period. Finally, Parnassus Investments LLC boosted its stake in shares of Danaher by 23.3% during the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock worth $784,745,000 after acquiring an additional 722,636 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 7.4%

DHR stock opened at $212.92 on Thursday. The company’s 50 day simple moving average is $199.85 and its 200-day simple moving average is $197.42. The firm has a market capitalization of $152.46 billion, a PE ratio of 45.30, a P/E/G ratio of 2.82 and a beta of 0.77. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is presently 27.23%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DHR. Deutsche Bank Aktiengesellschaft lowered their price target on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Evercore ISI cut their price target on Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Barclays reiterated an “overweight” rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Finally, Guggenheim restated a “buy” rating and set a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average target price of $245.91.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.